SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (302)5/11/1998 6:57:00 PM
From: squetch  Read Replies (2) | Respond to of 717
 
Peter, The volume of the calls is so low. I bought more shares late Friday on what looked like good price action. Plus it was about the only cancer biotech that hadn't been mentioned yet. I don't think a lot of people who bought on the CNBC news had read the H&Q report.(:>) My question is whether the news at ASCO will cause it to spike more.

Jim McManat(sp) was on CNBC talking about doctors more likely to use a new drug w/ chemo[I assume radiation too] versus trying some totally new method. squetch



To: Biomaven who wrote (302)5/12/1998 4:18:00 PM
From: Curtis Frazier  Read Replies (1) | Respond to of 717
 
One would think looking in from the outside that if the news is almost so certain to be great, the stock would continually rise in a manner similiar to ENMD. This one has me very suspicious.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News